UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 440

Sortiert nach

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Nature reviews. Clinical oncology, 2022-08, Vol.19 (8), p.499-514

2022

Volltextzugriff (PDF)

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

Journal of clinical oncology, 2020-09, Vol.38 (25), p.JCO1903123-2936

2020

Volltextzugriff (PDF)

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

The lancet oncology, 2015-04, Vol.16 (4), p.e165-e172

2015

Volltextzugriff (PDF)

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates

Cancer discovery, 2021-09, Vol.11 (9), p.2145-2157

2021

Volltextzugriff (PDF)

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Nature reviews. Clinical oncology, 2014-08, Vol.11 (8), p.473-481

2014

Volltextzugriff (PDF)

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

The lancet oncology, 2020-03, Vol.21 (3), p.373-386

2020

Volltextzugriff (PDF)

The Shifting Landscape for Lung Cancer: Past, Present, and Future

American journal of respiratory and critical care medicine, 2017-05, Vol.195 (9), p.1150

2017

Volltextzugriff (PDF)

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Journal of clinical oncology, 2018-06, Vol.36 (17), p.1675-1684

2018

Volltextzugriff (PDF)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Oncogene, 2019-09, Vol.38 (37), p.6399-6413

2019

Volltextzugriff (PDF)

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Cancer cell, 2021-11, Vol.39 (11), p.1531-1547.e10

2021

Volltextzugriff (PDF)

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

The lancet oncology, 2015-07, Vol.16 (7), p.830-838

2015

Volltextzugriff (PDF)

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Cancer, 2019-03, Vol.125 (6), p.892-901

2019

Volltextzugriff (PDF)

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3327-3334

2013

Volltextzugriff (PDF)

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Clinical cancer research, 2021-05, Vol.27 (10), p.2899-2909

2021

Volltextzugriff (PDF)

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Volltextzugriff (PDF)

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The lancet oncology, 2015-02, Vol.16 (2), p.141-151

2015

Volltextzugriff (PDF)

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines

Chest, 2013-05, Vol.143 (5 Suppl), p.e341S-e368S

2013

Volltextzugriff (PDF)

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Clinical cancer research, 2015-09, Vol.21 (17), p.3924-3933

2015

Volltextzugriff (PDF)

Deploying blood-based cancer screening

Science (American Association for the Advancement of Science), 2024-01, Vol.383 (6681), p.368-370

2024

Volltextzugriff (PDF)

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

Science (American Association for the Advancement of Science), 2015-09, Vol.349 (6254), p.1351-1356

2015

Volltextzugriff (PDF)

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

Science (American Association for the Advancement of Science), 2013-02, Vol.339 (6119), p.580-584

2013

Volltextzugriff (PDF)

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer

Cancer discovery, 2018-10, Vol.8 (10), p.1286-1299

2018

Volltextzugriff (PDF)

LTK fusions: A new target emerges in non-small cell lung cancer

Cancer cell, 2022-01, Vol.40 (1), p.23-25

2022

Volltextzugriff (PDF)

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(410)
Mit Volltextzugriff
(399)

Publikationsform

Sprache

Englisch
(438)
Japanisch
(76)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(242)
Humans
(223)
Life Sciences & Biomedicine
(220)
Oncology
(189)
Lung Neoplasms - Drug Therapy
(131)
Female
(123)
Male
(115)
Lung Neoplasms - Genetics
(103)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(100)
Mutation
(100)
Middle Aged
(88)
Aged
(82)
Lung Neoplasms - Pathology
(81)
Carcinoma, Non-Small-Cell Lung - Genetics
(73)
Lung Cancer
(73)
Adult
(62)
Aged, 80 And Over
(61)
Respiratory System
(56)
Carcinoma, Non-Small-Cell Lung - Pathology
(52)
Protein Kinase Inhibitors - Therapeutic Use
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(97)
Journal Of Thoracic Oncology
(67)
Cancer Research
(34)
Clinical Cancer Research
(26)
Cancer Discovery
(19)
The Oncologist
(16)
The oncologist
(13)
The New England Journal Of Medicine
(11)
Clinical Lung Cancer
(9)
Nature Communications
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

The Shifting Landscape for Lung Cancer: Past, Present, and Future

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Deploying blood-based cancer screening

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer

LTK fusions: A new target emerges in non-small cell lung cancer

Suchergebnisse filtern